



SEQUENCE LISTING

<110> Meloen, Robert H

Oonk, Hendrica B

<120>

PEPTIDE, IMMUNOGENIC COMPOSITION AND VACCINE OR MEDICAL PREPARATION, A METHOD TO IMMUNISE ANIMALS AGAINST THE HORMONE LHRH, AND ANALOGS OF THE LHRH TANDEM REPEAT PEPTIDE AND THEIR USE AS VACCINE

<130> 3516.2US

<140> US 09/876,257

<141> 2001-06-06

<160> 6

<170> PatentIn version 3.1

<210> 1

<211> ,10

<212> PRT

<213> Unknown

<220>

<223> Luteinising Hormone Releasing Hormone (LHRH) from the hypothalamus of an undisclosed mammal.

<220>

<221> misc feature

<222> (1)..(1)

<223> X at position 1 = pyroglutamic acid

<220>

<221> misc feature

<222> (10)..(10)

<223> X at position 10 = glycine amide

<400> 1

Xaa His Trp Ser Tyr Gly Leu Arg Pro Xaa

1 5 10

<210> 2

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> Vaccine against LHRH from the hypothalamus of an undisclosed mammal.

<220>

B1

Okay to  
enter  
JRL  
1-15-2003

<221> misc feature

<222> (1)..(1)

<223> X at position 1 = preferably pyroglutamic acid, but can also be glutamine having attached thereto a tail comprising one or more additional amino acids

<220>

<221> misc feature

<222> (3)..(3)

<223> X at position 3 = tryptophan or formylated tryptophan

<220>

<221> misc feature

<222> (14)..(14)

<223> X at position 14 = tryptophan or formylated tryptophan

<220>

<221> misc feature

<222> (10)..(20)

<223> The sequence comprising residues 10-20 may be repeated.

<220>

<221> misc feature

<222> (21)..(21)

<223> X at position 21 = either nothing or a tail comprising additional amino acid; preferably Cys, the C terminal cysteine being added in connection with a possible coupling of the peptide to a carrier protein.

<400> 2

Xaa His Xaa Ser Tyr Gly Leu Arg Pro Gly Gln His Xaa Ser Tyr Gly  
1 5 10 15

Leu Arg Pro Gly Xaa  
20

<210> 3

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> Vaccine against LHRH from the hypothalamus of an undisclosed mammal.

<220>

B1  
cont.

<221> misc feature  
<222> (1)..(1)  
<223> X at position 1 = pyroglutamic acid

<220>  
<221> misc feature  
<222> (3)..(3)  
<223> X at position 3 = tryptophan or N-formyl-Trp

<220>  
<221> misc feature  
<222> (13)..(13)  
<223> X at position 13 = tryptophan or N-formyl-Trp

<220>  
<221> misc feature  
<222> (10)..(19)  
<223> The sequence comprising residues 10-19 may be repeated.

<400> 3

Xaa His Xaa Ser Tyr Gly Leu Arg Pro Gly Gln His Xaa Ser Tyr Gly  
1 5 10 15

Leu Arg Pro Gly Cys  
20

<210> 4  
<211> 21  
<212> PRT  
<213> Artificial Sequence  
<220>  
<223> Vaccine against LHRH from the  
hypothalamus of an undisclosed mammal.

<220>  
<221> misc feature  
<222> (1)..(1)  
<223> X at position 1 = pyroglutamic acid

<220>  
<221> misc feature  
<222> (6)..(6)

81  
cont.

<223> X at position 6 = a possible replacement of glycine by a dextrorotatory amino acid which in addition contains a side chain by which the LHRH tandem unit can be coupled to a carrier compound.

<220>

<221> misc feature

<222> (16)..(16)

<223> X at position 16 = a possible replacement of glycine by a dextrorotatory amino acid which in addition contains a side chain by which the LHRH tandem unit can be coupled to a carrier compound.

<400> 4

Xaa His Trp Ser Tyr Xaa Leu Arg Pro Gly Gln His Trp Ser Tyr Xaa  
1 5 10 15

Leu Arg Pro Gly Cys  
20

<210> 5

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Vaccine against LHRH from the hypothalamus of an undisclosed mammal.

<220>

<221> misc feature

<222> (1)..(1)

<223> X at position 1 = pyroglutamic acid

<220>

<221> misc feature

<222> (6)..(6)

<223> X at position 6 = Gly or a dextrorotatory amino acid containing a side chain that allows coupling to a carrier compound.

<400> 5

Xaa His Trp Ser Tyr Xaa Leu Arg Pro Gly Cys  
1 5 10

<210> 6

<211> 22

<212> PRT

<213> Artificial Sequence

<220>

<223> Vaccine against LHRH from the  
hypothalamus of an undisclosed mammal.

<220>

<221> misc feature

<222> (21)..(21)

<223> X at position 21 = Cys

<220>

<221> misc feature

<222> (1)..(21)

<223> The initial cysteine of the peptide comprising  
residues 1-21 is joined to the initial cysteine of an identical peptide (residues 2  
2-42) to form a dimer.

<400> 6

Cys Gln His Trp Ser Tyr Gly Leu Arg Pro Gly Gln His Trp Ser Tyr

1 5 10 15

Gly Leu Arg Pro Gly Xaa

20

B1  
concl.